Close Menu

Angle

The groups combined their circulating tumor cell collection and detection platforms to find higher cell numbers in metastatic breast, lung, and melanoma cancer patients. 

Angle's Parsortix yielded lower white blood cell backgrounds in samples, but Biolidics' ClearCell detected melanoma CTCs in additional samples that Parsortix missed. 

More groups are now using CTC capture methods alongside circulating tumor DNA tools to distinguish themselves from the crowded ctDNA detection space.

The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.

The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.

Researchers used the system to improve a method for analyzing lymph nodes and believe it could improve the care of patients with these and other early-stage cancers.

The firm believes its Parsortix cell separation system, so far used for oncology, can extract rare fetal cells from maternal blood to detect genetic disorders.

Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.